Rallis IndiaQ1 FY25

Rallis India Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹191.25P/E: 18.1Market Cap: ₹3.7K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • Domestic business is expected to improve with positive monsoon sentiments and new MSP, leading to significant volume growth.
  • Export volumes showed a 19% growth in the quarter; continuation depends on molecule-specific market dynamics.
  • Crop care domestic business grew 13% in volume; herbicides and recent product launches like Clasto are key growth drivers.
  • Crop nutrition segment grew around 31%, considered a strong pillar for long-term growth with better margins.
  • Cotton packets sales are expected to grow significantly, especially in North cotton.
  • Supply constraints in seeds like hybrid maize and paddy have impacted growth; efforts ongoing to resolve these.
  • Focus on portfolio optimization, including new product launches and phasing out low-margin products, aims to enhance growth.
  • Collaborative partnerships for product development and supply chain certainty are part of growth strategy.
  • Overall, the company is confident and optimistic about medium-to-long-term growth prospects.

See what Rallis India management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • The company currently has a very healthy cash balance as of June 30, 2024.
  • There are no external borrowings outstanding.
  • The company is being very prudent in its CAPEX investments, with envisaged expenses around Rs.100 crore.
  • There is no mention of any plans for new fundraising through debt or equity in the provided transcript.
  • The focus appears to be on improving capital efficiencies and managing working and fixed capital effectively rather than raising new funds.

See what Rallis India management said on order book — free account, 30 seconds.

Capex plans

Yes
  • The company is very prudent in CAPEX investment, envisaging expenses around Rs.100 crore.
  • Investments are being made in automation to improve manufacturing efficiency and timely delivery.
  • Digital investments are continuing, focusing on customer connectivity and leveraging digital tools for better planning and forecasting.
  • Plans to build an integrated R&D facility in Bangalore, combining two R&D centers, expected to be ready in two years.
  • Strategic focus on partnerships and collaborations with global and domestic companies to refresh and strengthen the product portfolio.
  • Investment in expanding formulation alliances in the contract manufacturing business to improve capacity utilization at the Dahej chemical zone facility.
  • Continued focus on evolving portfolio with differentiated products and phasing out low-margin or less profitable ones.

Track Rallis India — get its next earnings analysis in your feed

How does Rallis India rank vs peers in Fertilizers & Agrochemicals?

Pro feature
ThisRallis India
Rev 3Mar 2

How does Rallis India rank in Fertilizers & Agrochemicals?

Compare Rallis India against every Fertilizers & Agrochemicals company (Q1 FY25) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

Others in Fertilizers & Agrochemicals this season

  • Madhya Bharat Agro Products (Q2 FY27)

    Q2 FY27 Revenue: ₹715 crore, up 59% YoY (Page 12, Chairman’s Quote) . Key investor presentation takeaways from Madhya Bharat Agro Products Ltd's Q2 FY27 investo

  • Dhansa Labs (Q2 FY27)

    1,864 crores during H1 FY27. Key results statement takeaways from Dhansa Labs Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Aristo Bio-Tech (Q2 FY27)

    1,168.88 lakh, approximate operating margin is about 5.9% for the quarter. Key results statement takeaways from Aristo Bio-Tech & Lifescience Ltd's Q2 FY27 resu

  • Krishana Phoschem (Q2 FY27)

    Q2 FY27 Revenue: ₹703 crore, a 16% year-on-year (YoY) increase (Page 11). Key investor presentation takeaways from Krishana Phoschem Ltd's Q2 FY27 investor pres

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →